Login / Signup

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.

Zhen-Duo ShiLin HaoXiao-Xiao HanZhuo-Xun WuKun PangYang DongJia-Xin QinGuang-Yue WangXuan-Ming ZhangTian XiaQing LiangYan ZhaoRui LiShao-Qi ZhangJun-Hao ZhangJian-Gang ChenGong-Cheng WangZhe-Sheng ChenCong-Hui Han
Published in: Molecular cancer (2022)
Our study demonstrated that HNRNPU expression is associated with cisplatin sensitivity in bladder urothelial carcinoma cells. Inhibition of HNRNPU could be a potential therapy for cisplatin-resistant bladder cancer.
Keyphrases
  • poor prognosis
  • urinary tract
  • high grade
  • risk assessment
  • binding protein
  • human health
  • long non coding rna